Skip to content

Corticosteroids in Severe COVID-19(ASAP-C Study)

Administration of Systemic Corticosteroids Among Critically Ill Patients With COVID-19: Electronic Survey (ASAP-C Study)

Status
UNKNOWN
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT04648410
Acronym
ASAP-C
Enrollment
2000
Registered
2020-12-01
Start date
2021-02-16
Completion date
2023-12-01
Last updated
2023-07-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Severe COVID-19

Brief summary

Administration of systemic corticosteroids for patients with severe forms of severe acute respiratory syndrome(SARS-Co-2) infection are recommended by several guidelines. In the very beginning of SARS-Co-2 pandemic the early recommendation by professional organization was against routine use of corticosteroids for patients with coronavirus disease 2019 (COVID-19) acute respiratory distress syndrome (ARDS), despite previous data and clinical practice for patients with refractory or severe form of ARDS.

Detailed description

Administration of systemic corticosteroids for patients with severe forms of SARS-Co-2 infection are recommended by several guidelines. In the very beginning of SARS-Co-2 pandemic the early recommendation by professional organization was against routine use of corticosteroids for patients with coronavirus disease 2019 (COVID-19) ARDS, despite previous data and clinical practice for patients with refractory or severe form of ARDS. But at the latest after publication of RECOVERY trial (Randomized Evaluation of Covid-19 Therapy, July 2020) and ensued metaanalysis of World Health Organization (WHO) working group, the routine administration of systemic corticosteroids was revisited. However, there are ongoing critical debate of the evidence regarding the dose, administration, timing and type of corticosteroids and ongoing randomized controlled trial (RCT) are challenging the recommendation of 6 mg of dexamethasone for all patients with severe form of COVID-19. The dynamic of COVID-19 surges, flip-flop of official recommendations within very short period of time and ongoing critical debate could be with possible variations of daily clinical practice regarding using systemic corticosteroids. In an electronic evaluation form that will be send to European Society of Intensive Care (ESICM) Members. The electronic survey will contain 10 question. In the questionnaire the participants will have to describe their routine clinical practice regarding administration of systemic corticosteroids among patients with COVID-19 ARDS.

Interventions

OTHERquestionnaire

Members of European Society of Intensive Care will obtain an electronic survey considering their routine clinical practice regarding the administration of systemic corticosteroids among patients with COVID-19 ARDS

Sponsors

Brno University Hospital
Lead SponsorOTHER

Study design

Observational model
OTHER
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
28 Days to 100 Years
Healthy volunteers
No

Inclusion criteria

* Members of European Society of Intensive Care

Exclusion criteria

* not members of European Society of Intensive Care

Design outcomes

Primary

MeasureTime frameDescription
Systemic corticosteroids among patients with COVID-19 ARDS practice - questionnaire (electronic survey)1 monthAdministration of systemic corticosteroids among patients with COVID-19 ARDS practice in European countries - questionnaire (electronic survey)

Countries

Czechia

Contacts

Primary ContactJan Malaska, MD., Ph.D
jan.malaska@gmail.com532232009
Backup ContactJozef Klučka, assoc.Prof.MD, Ph.D
klucka.jozef@fnbrno.cz532234696

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026